Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Semin Oncol. 2006 Oct;33(5 Suppl 10):S8-S14.  

Norum J. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. J Chemother. 2006 Oct;18(5):532-7.   

Warusavitarne J, Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis. 2006 Nov 16;

D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, Dematteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB. Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Ann Surg Oncol. 2006 Nov 11;

Prosnitz RG, Patwardhan MB, Samsa GP, Mantyh CR, Fisher DA, McCrory DC, Cline KE, Gray RN, Morse MA.  Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review.
Cancer. 2006 Nov 15;107(10):2352-60.

Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P, Chilcott J. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer. 2006 Nov 6;95(9):1195-201.